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Abstract 
Implantable electrodes interface with the human body for a range of therapeutic as well as 
diagnostic applications. Here we provide an overview of controlled delivery strategies used in 
neuro-bionics. Controlled delivery of bioactive molecules has been used to minimise reactive 
cellular and tissue responses and/or promote nerve preservation and neurite outgrowth toward 
the implanted electrode. These effects are integral to establishing a chronically stable and 
effective electrode-neural communication. Drug-eluting bioactive coatings, organic 
conductive polymers, or integrated microfabricated drug delivery channels are strategies 
commonly used. 
 
Keywords: Neuro-bionics, controlled release, organic conductive polymers, drug-eluting 
coatings, nerve preservation, electrode-neural interfacing, foreign body response 
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1. Introduction 
Medical bionic systems provide a link between electronic devices and the human body in 
order to restore or enhance sensory and/or motor function lost through disease or injury. A 
great deal of attention has been paid to the development of neuro-bionics for monitoring, 
stimulatory and recording applications.  
 
1.1. Neuro-bionic devices 
A number of implantable bionic devices aim to improve human performance by monitoring 
some aspect of our biological system. The placement of an electrode grid consisting of four 
platinum-iridium electrodes into the brain enables pre-emptive detection of epileptic seizures 
[1]. Electric impulses emanating from the brain are recorded in order to give warning of an 
impending seizure. Such a device has significant benefits for the treatment of epilepsy 
through the management of medication, or potentially other therapeutic options such as 
neurostimulation.  
 
Systems have been developed to apply a predetermined electrical stimulation for the 
treatment of neurological disorders. Examples of routine clinical use include deep brain 
stimulators to relieve symptoms of Parkinson’s disease, spinal cord stimulators to alleviate 
chronic neuropathic pain [2,3], and vagal nerve stimulators to treat intractable epilepsy and 
treatment-resistant depression [4]. In cancer treatment, deep brain and spinal cord stimulation 
using implanted electrodes have long been used for modulation of chronic pain [5,6]. In 
addition, implantable electrodes can also be applied to enhance the tumoricidal effect of 
hyperthermia via elevating the lethal temperature levels in the tumors [7], and to improve the 
efficacy of radiation therapy via in situ tumor oxygenation [8].  
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The bionic ear (cochlear implant) electrically provides sound to the profoundly deaf through 
stimulating the auditory nerve [9]. It comprises a microphone to collect sound, a speech 
processor to transcode the sound to electronic impulses, a transmission coil, an array of 
electrodes that stimulate targeted areas of the auditory nerve, and a power supply (Fig. 1). 
More recently, the development of the bionic eye has been actively pursued. Two main types 
of visual prostheses, retinal and cortical implants, are currently under investigation. For 
retinal implants, imaging data is processed for electrical stimulation of the optical nerve via 
electrode arrays implanted on the retina [10], whereas for cortical implants, microelectrode 
arrays are implanted in the visual cortices [11]. 
 
 
Fig. 1. Cochlear implant (Bionic Ear). (A) Schematic of the components of a cochlear 
implant, image courtesy of Cochlear Ltd, Australia. (a) The microphone to capture sound. (b) 
The external transmitter to convert the sound into radio-frequency signal. (c) The implantable 
portion of the cochlear implant consisting of a receiver/stimulator to convert the radio-
frequency signal to electrical impulses and send them along the electrode array positioned in 
the cochlea. – (d) The implant's electrodes to stimulate the cochlea’s auditory nerve and send 
the impulses to the brain for sound perception. (B) Nucleus® 5 cochlear implant (CI512) 
showing the internal components of the system. (1) Receiver stimulator in titanium casing. 
(2) Implant coil enabling telemetry. (3) Two extracochlear electrodes for different stimulation 
modes. (4) 22 half-banded platinum electrode contacts providing focused stimulation to the 
spiral ganglion cell region of the cochlea, the part mostly needing drug delivery for better 
electro-neural interfacing. (5) Removable magnets for MRI safety. (6) Symmetrical exit leads 
from main casing. Reproduced with permission from www.bionicsinstitue.org. 
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Apart from the above monitoring and stimulating implants, an emerging field is brain-
computer and peripheral nerve interfacing systems that utilise recording electrodes to decode 
signals from the brain for direct control of motor prosthesis or body muscles to restore 
movement [12]. These systems will ultimately allow patients with severe movement 
limitations, such as paralysis, to perform many activities of daily living now requiring 
caretakers, such as dexterous hand and finger movements, standing, walking and gait. The 
proof of concept of such neurotechnologies has been demonstrated in a number of studies 
conducted in non-human primates or paralyzed patients [13,14,15]. For example, with 
intracortical microelectrode arrays implanted in the primary motor cortices, Macaca mulatta 
monkeys demonstrate the ability to control a robotic arm for self-feeding [13]. In a recent 
pilot clinical trial, patients with tetraplegia have shown to be able to control a computer’s 
cursor and rudimentarily operate a multi-jointed robotic arm using the motor cortical signals 
recorded through an implanted 96-microelectrode array [15].  
 
1.2. Electrode-neural interfacing 
The Achilles heel of all bionic devices is the electrode-cellular/tissue interface [16]. 
Bioelectronic communication between the implanted electrode and the neural targets is 
compromised over extended periods [17], primarily due to encapsulation of the electrode 
with connective tissue. For example, the host responses to the cochlear implant are 
characterised by fibrosis and new bone formation, which increases electrical impedance and 
power consumption, limiting the efficacy of safe stimulation at the auditory nerve [9]. For 
brain implants, such as intracortical probes, the host body response takes the form of reactive 
gliosis, involving with the formation of an astroglial scar that electronically insulates the 
electrode from nearby neurons [18].  
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A degradation in performance with time may also be attributed to neuronal loss arising from 
acute and chronic inflammatory responses associated with implantation, and also from further 
degeneration of neurons as a result of central or peripheral nerve pathologies [19]. The long-
term performance of the bionic ear directly correlates to the survival rate of the remanent 
spiral ganglion cells following sensorineural hearing loss, while the bionic eye relies 
critically on retinal ganglion cell survival [20]. 
 
The ideal electrode-neural interface requires both a minimal foreign body response and 
intimate communication between electrodes and a sufficient amount of neuron targets to 
permit efficient stimulation and recording. Numerous studies have been undertaken with a 
view to controlling the nature of this electrode interface through the delivery of bioactive 
molecules during or subsequent to implantation. These studies have primarily focused on 
local delivery of neurotrophic factors (to facilitate neurite outgrowth and neural preservation) 
and/or anti-inflammatory drugs in the vicinity of the implanted device.  
 
A variety of bioactive coatings have been developed for bionic devices. Three approaches are 
reviewed here. The first involves drug-eluting structures formulated with anti-inflammatory 
drugs [21,22,23,24,25] and neurotrophin-eluting hydrogels [26,27,28,29,30,31]. The second 
approach involves integration of microfluidic channels into neural prostheses for in situ 
delivery of bioactive molecules with high temporal and spatial resolution 
[32,33,34,35,36,37,38,39]. Finally the use of organic conductive polymer (OCP) coatings, a 
novel class of materials that significantly decrease the impedance of electrodes, and also can 
provide controlled delivery of bioactive molecules at the electrode-neural interface 
[40,41,42,43,44,45,46,47,48,49,50]. 
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2. Controlled delivery systems based on conventional polymers 
Numerous sustained delivery systems for use in tandem with bionic devices have been 
developed. They involve the use of either bioactive coatings or modified electrode housing 
structures that act as reservoirs for the delivery of neurotrophins and/or anti-inflammatory 
drugs.  
 
Microfabricated systems integrated with neurobionic devices are also included, as they reflect 
the increasing need for greater spatial/temporal control over the delivery of complex 
biological cues as required for optimising neuro-electrode interfaces. 
 
2.1. Bioactive coatings 
Nitrocellulose coatings have been developed for sustained delivery of anti-inflammatory 
agents, such as α-melanocyte stimulating hormone (α-MSH) and dexamethasone (DEX), 
from silicon recording electrode arrays [21,22,23]. These coatings comprise a drug-embedded 
matrix of nitrocellulose surrounded by layers of pure nitrocellulose (Fig. 2) [21]. The level of 
control in drug release can be modulated by varying the number of layers of nitrocellulose as 
well as the porosity of the coatings. In vitro testing of the MSH-nitrocellulose coatings 
showed sustained release of the drug over 21 days, with the anti-inflammatory activity 
against lipopolysaccharide-stimulated microglia retained over this period. Silicon neural 
probes coated with DEX-nitrocellulose were tested in vivo to assess the influence of coating 
on brain tissue response [23]. The coatings reduced the astroglial scar formation and the level 
of neuronal loss at the electrode-brain interface, as a result of the localised release of the 
DEX. These anti-inflammatory effects were achieved without affecting the electrical 
performance of the electrodes. 
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Fig. 2. Schematic illustration of nitrocellulose-based drug-eluting coatings for Si-multi-
electrode arrays. Adapted with permission from [21]. 
 
To improve the quality of chronic neural recording, nanotechnology has been exploited to 
control the release of DEX around implanted electrode arrays [24,25]. DEX-loaded 
poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) were prepared using an oil-in-water 
technique, and those embedded into an alginate hydrogel coating deposited on the neural 
electrodes [24]. The NP-loaded coatings exhibited a sustained DEX release profile for up to 3 
weeks, a process that is governed by a combination of retarded degradation of NPs due to 
entrapment in the hydrogel matrix. Unlike the uncoated electrodes, DEX-loaded electrodes 
were able to maintain the initially low in-vivo impedance over a period of 3 weeks after 
implantation (Fig. 3). In addition to the local administration of DEX, the presence of the 
hydrogel coating itself is advantageous in reducing the inflammatory reaction to the 
implanted electrodes by providing mechanical buffering between the stiff electrodes and soft 
brain tissue. 
nitrocellulose
drug dispersed in nitrocellulose
Si wafer
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Fig. 3. Optical images of hydrogel-coated neural microelectrode arrays: (a) without DEX-
loaded nanoparticles, (b) with DEX-loaded nanoparticles in the hydrogel coating. (c) In vivo 
impedance at 1 kHz of DEX-loaded electrode chronically implanted in the auditory cortex in 
the guinea pig as a function of time. Adapted with permission from [24]. 
 
(c) 
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A similar approach was taken by Mercanzini et al. [25] in the preparation of drug-eluting 
coatings for microfabricated cortical neuroprostheses. The coatings were formulated with 
poly(ethylene oxide) (PEO) and DEX-loaded NPs of poly(propylene sulphide). DEX loading 
was achieved using a co-solvent-evaporation procedure [51]. The release profile was 
determined by both the oxidation of poly(propylene sulphide) and diffusion. The 
effectiveness of these NP-embedded coatings in managing the local tissue reaction to 
implanted devices was demonstrated by histological and in vivo impedance experiments. In 
comparison to uncoated devices, a substantial reduction (25%) in the impedance at the Peak 
Resistance Frequency was noted at the end of the 46 day experiment. 
 
Hydrogels are highly hydrated polymeric networks with structural and mechanical properties 
mimicking soft tissue. Their capability to provide sustained delivery of bioactive molecules, 
such as proteins, has been intensively exploited in a broad range of biomedical applications. 
Their mechanical properties make them attractive coating materials in controlled delivery for 
both stimulation and recording devices, in order to improve neural survival and neuron-
electrode proximity. Research in this area is still at an early stage, but will greatly benefit 
from the enriched knowledge and experience accrued in the field of hydrogel, especially for 
the applications in protein delivery/therapy and tissue engineering.  
 
Several photo-crosslinkable gel systems have been investigated in vitro [26,27,28,29,30,31]. 
For example, biodegradable neurotrophin-eluting hydrogel coatings, based on poly(ethylene 
glycol)-poly(lactic acid) (PEGPLA), were developed for multi-electrode arrays with sputtered 
iridium oxide charge-injection sites [26,27]. This was achieved by applying the aqueous 
solution of PEGPLA precursor and neural growth factor (NGF)/brain-derived neurotrophic 
factor (BDNF) to the electrode array surface and inducing crosslinking via UV irradiation. 
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The coatings were shown to adhere well to the electrode array surface, and were able to elute 
neurotrophin at biologically significant concentrations for at least one week. Importantly, the 
coatings had little impact on the iridium oxide electrochemical properties, including charge 
storage capacity, impedance, and voltage transition during current pulsing.  
 
A number of parameters can be employed to regulate the release profile of neurotrophin-
eluting hydrogel coatings. Reducing the biodegradability of coating materials can 
significantly prolong the duration of sustained release as achieved by introducing a poly(ε-
caprolactone) (PCL) component into the PEGPCL hydrogel coating [28]. Similarly 
introduction of the PCL component via electrospinning extends the duration of sustained 
release [29]. Other approaches used to control the delivery of neurotrophin involve chemical 
modification to promote protein-matrix interactions, and varying the porosity of hydrogel 
coatings. For example, modification of poly(2-hydroxyethyl methacrylate) (pHEMA) 
hydrogel coatings with lysine resulted in more extended release of NGF, while introducing 
macroporosity into the pHEMA hydrogel coatings shortened the release of NGF [31].   
 
Controlling the biodegradability of the hydrogel has been shown to be a viable approach in 
improving the coating-electrode adhesion [28]. When tested using an agarose tissue phantom, 
PEGPCL hydrogels were able to adhere to the electrode devices for at least 4 weeks, which 
was attributable to a slower degradation rate of the PCL component, and a significant 
improvement than PEGPLA coatings that adhered up to 11 days [28]. Another approach to 
improving the stability of hydrogel coatings involves surface treatment of electrode substrate 
to permit the chemical bonding with the coating [30,31]. 
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2.2. Integrated microfabricated systems 
Silicon intracortical probes with integrated microfluidic channels have been fabricated to 
enable controlled localised delivery [32,33,52,53,54]. In vivo experiments have demonstrated 
the feasibility of delivering chemicals into relevant volumes of reactive tissue [32,33,53]. 
Drug release in these fluidic channels can be mediated by diffusive or convective transport. 
The latter offers a significant degree of versatility, and precise control of the biochemical 
environment of tissue up to a millimetre away from the inserted site [33,52]. However, it 
requires additional parts such as integrated pumps, valves, or connections to an outside 
device for control of the release, which raises concerns over added complexity of device 
fabrication, higher failure rate, and increased size of devices that may cause more insertion 
injury and consequently increased tissue reactions and risk of infection. 
 
Microfluidic channels have also been built into parylene flexible neural recording probes 
[34]. Compared to rigid silicon probes, these flexible neural probes are of increasing interest 
as they conform to the shape and deformation of soft tissue. In addition to providing a means 
for in vivo drug delivery, the fluidic channel also provides transient and yet sufficient 
mechanical stiffness for insertion, through filling the channel with a biocompatible, solid 
poly(ethylene glycol) (PEG). After the insertion, the probe regained its original flexibility 
following the dissolution of PEG. In vivo experiments showed ease of insertion of the probe, 
and that inclusion of the drug release channel did not affect the quality of neural recording, as 
compared with conventional rigid probes. Future work should evaluate the long-term 
performance of the probe with and without the aid of drug delivery. The knowledge gained 
will provide insights into future development of neural probes with chronic recording 
functionality. 
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Post-operative degeneration of spiral ganglion neurons is best prevented in order to achieve 
optimal performance of cochlear implants. To promote preservation of the auditory nerve, a 
number of studies have focused on modification of cochlear implants with an integrated drug 
delivery channel for intracochlear pharmaceutical intervention [36,37,38,39]. The channel is 
linked to a micro-osmotic pump or an infusion pump to control the flow rate. The feasibility 
of concurrently delivering drugs and stimulating the auditory nerve has been demonstrated in 
animal models [36,39]. An example of a cochlear drug delivery device, based on a Nucleus 
Contour electrode, is described here. The electrode has an inbuilt lumen for a stylet that 
straightens the electrode array for insertion. The stylet is then removed, leaving the lumen to 
be connected to an Alzet pump mini-osmotic pump. The applicability of this device to the 
human cochlea was evaluated in vitro using samples of human temporal bone [37]. Passche et 
al. [55] compared dye delivery in three different electrode prototypes with openings at 
various position along the electrode array using an in vitro plastic cochlear model, i.e. release 
of dye at the tip; release of the dye at the tip and the side of the electrode; and release of the 
dye only at the side of the electrode (Fig. 4). Dye concentration in apical, middle, and basal 
regions at different times was shown to be influenced by pump rate, numbers and location of 
outlets. The results indicated that the best distribution of dye within the cochlea was reached 
when using multiple outlets with an opening at the tip being mandatory. To facilitate 
manufacturing multiple outlets at desired locations and sizes, a technology has been 
developed using femtosecond laser [56].  
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Fig. 4.   Dye is delivered from three different prototypes at a pump rate of 100 µl/h. (A) 
Opening at the tip; (B) release at the tip and the side; (C) release only at the side of the array. 
The openings for fluid delivery are indicated by arrows. Reproduced with permission from 
[55].    
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Using an alternative approach Williams et al. developed Micro-MEMS (electro-mechanical 
systems)-based neural probes with built-in micromachined wells within micrometers of 
individual electrodes [57]. These wells extended through the device’s thickness, and thus 
permitted the deposition of hydrogels infused with bioactive molecules without increasing the 
footprint of the device. The release profile in the wells was mediated by diffusion, and can be 
manipulated by controlling well geometry and hydrogel materials to effect both the duration 
and rate of drug release. In vivo testing verified the integration of the bioactive molecules 
with intended neural targets and concurrent extracellular recoding using nearby electrodes. 
Perhaps, the most significant benefit of this technology, yet to be demonstrated, is spatial and 
temporal control over the presentation of different drugs, multiple biological cues, or 
gradients of growth factors at selected sites; to both effectively direct neurite growth toward 
the electrodes and alleviate the reactive cell and tissue responses. This could be achieved by 
loading each well individually with a different and appropriately formulated bioactive 
molecule. The importance of complex biological cues in addressing electrode-neural 
interfacing has been increasingly recognised, and is also supported by recent studies that 
implied the short-lived effect of neurotrophins eluted from hydrogel coatings of 
neuroprosthetic devices, and the necessity of presenting other biological mechanisms in order 
to sustain the effect of eluted neurotrophins [27,28].  
 
3. Electrically on-demand delivery systems based on OCPs 
The most commonly studied OCPs for biomedical applications are polypyrrole (PPy) and the 
functionalised thiophene, Poly(3,4-ethylenedioxythiophene) (PEDOT) [58]. These OCPs 
have been studied in a wide range of cell types and are considered to be chemically stable and 
non-cytotoxic. Therefore their potential clinical application predominantly lies in the area of 
excitable cell interactions, namely nerve repair. The biggest limitation of conductive 
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polymers for in vivo applications is their inherent inability to degrade, which may induce 
chronic inflammation and require surgical removal [59]. To address the drawbacks of 
existing conductive polymers, attempts to blend them with suitable biodegradable polymers 
have been carried out [59,60,61]. 
 
OCPs are unique amongst bionic electromaterials in that they provide a conduit for direct 
electrical stimulation and a concomitant means of controlled, triggered bioactive molecule 
delivery within the same platform. OCPs, in their oxidised (conducting) form require counter 
ions to be incorporated into the polymer backbone to achieve charge neutrality. This provides 
a mechanism for the incorporation and release of bioactive anions via electrically triggered 
redox cycling (Fig. 5A and B). To broaden the scope of molecules suitable for OCP mediated 
delivery to include neutral and cationic therapeutic agents, a biotin-doped platform has been 
developed based on polypyrrole (PPy) [62]. Biotinylated drugs can be attached onto the 
polymer surface through biotin-streptavidin binding, and released upon electrical stimulation 
(Fig. 5C).   
 
Fig. 5. (A) Synthesis of an OCP showing the incorporation of dopant A-. (B) Release of the 
dopant A- during redox cycling of the OCP. Reproduced with permission from [40]. (C) 
Electrically triggered release of biotinylated NGF from biotin-doped PPy. Reproduced with 
permission from [62]. 
 
PPy and poly(3,4-ethylenedioxythiophene) (PEDOT) are the most intensively investigated 
OCPs for neural interfacing applications. Coating of the electrode with PPy or PEDOT is 
C 
B 
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generally achieved by electrodeposition, a simple procedure that, when coupled with the 
controlled release capability of OCPs, can permit convenient and precise engineering of 
individual electrode sites for simultaneous optimisation of both the biochemical environment 
around and electrical performance of the electrode. Importantly, PPy and PEDOT have 
demonstrated compatibility with numerous cell types including neurons, neuronal-like cells 
and neural stem cells [63,64,65]. In vivo evaluation in rodent cortex has shown a positive 
biocompatibility profile with the central nervous system parenchyma that is comparable to 
Teflon or platinum control [66,67]. The tissue biocompatibility of PPy and PEDOT is further 
supported by their extensive applications in neural tissue engineering (as scaffolding 
materials) and regenerative bionics (as accessory electrode array systems) toward the 
regeneration of damaged nerve [68,69,70,71]. Together, it is these features that make PPy 
and PEDOT superior coating materials for the development of advanced neuro-bionics aimed 
at both high spatial selectivity and high signal fidelity over the long term. 
 
3.1. OCP coatings for delivery of anti-inflammatory drugs  
Precisely controlled local release of anti-inflammatory drugs at desired points in time is 
important for treating the inflammatory response of neural prosthetic devices in the central 
and peripheral nervous systems. Wadhwa et al. [45] reported on PPy coating doped with an 
anionic prodrug form of dexamethasone (PPy-Dex), dexamethasone 21-phosphate disodium, 
for chronic recording electrode arrays. The PPy-Dex coating has a thickness of 50 nm, and is 
capable of on-demand, dose-controlled release of the drug upon cyclic potential stimulation. 
The amount of drug released is directly proportional to the numbers of CV stimulus in the 
given CV cycle range (Fig. 6), and is sufficient to markedly reduce the number of reactive 
astrocytes and microglial, while provoking no toxic effect on healthy primary neurons in 
vitro.  
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Fig. 6. Release profile of dexamethasone 21-phosphate disodium (Dex) from the polymer-
drug coated electrodes. For PPy–Dex, the x-axis represents number of CV cycles. A control 
was set up to study the release from the film in the absence of any electrical stimulation. In 
this case the x-axis represents the number of minutes (at 100 mV/s scan rate, 1 CV cycle 
between -0.8 to 1.4 V takes approximately 1 min). Reproduced with permission from [45]. 
 
Abidian et al. [46] reported a method to fabricate OCP nanotubes onto a neural prosthetic 
electrode that could be used for precisely controlled drug release. Their fabrication process 
involved electrospinning of biodegradable poly(lactic-co-glycolic acid) (PLGA), into which 
dexamethasone was incorporated, followed by electrochemical deposition of PEDOT around 
the drug-loaded, electrospun PLGA fibers (Fig. 7). The PEDOT nanotubes significantly 
decreased the impedance (by ~2 orders of magnitude at 1 kHz, the characteristic frequency of 
neuronal-action potential), and increased the charge capacity (by ~3 orders of magnitude) of 
the recording electrode sites on microfabricated neural prosthetic devices. Dexamethasone 
could be released from the PEDOT nanotubes in a desired fashion by electrical stimulation of 
the nanotubes. The authors suggested that this drug release process presumably proceeds by a 
local dilation of the tube that then promotes mass transport. 
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Fig. 7. (A)-(C) Schematic diagrams illustrating the surface modification of neural 
microelectrodes to create nanotubular PEDOT and controlled release of Dex: (A) 
electrospinning of PLGA fibers with well-defined surface texture (1) on the probe tip; (B) 
electrochemical polymerization of PEDOT (2) around the electrospun fibers; and (C) 
dissolving the electrospun core fibers to create nanotubular conducting polymers (3). (D) 
Scanning electron micrographs of electropolymerized PEDOT nanotubes on the electrode site 
of an acute neural probe tip after removing the PLGA core fibers. (E) Cumulative mass 
release of dexamethasone from: PLGA nanoscale fibers (black squares), PEDOT-coated 
PLGA nanoscale fibers (red circles) without electrical stimulation, and PEDOT-coated PLGA 
nanoscale fibers with electrical stimulation of 1 V applied at the five specific times indicated 
by the circled data points (blue triangles). Adapted with permission from [46]. 
 
Whilst drug release systems based on OCPs have been extensively studied, the application of 
such systems has been limited due to some intrinsic technical barriers. For instance, the drug 
loading capacity of a conventional OCP film is limited, and the amount of drug released per 
stimulation is not sustainable over long periods [48]. In order to increase drug loading of PPy 
coatings, Luo et al. [48] incorporated carbon nanotubes (CNTs) into the PPy coatings to act 
as drug reservoirs (Fig. 8). Dexamethasone 21-phosphate disodium was loaded to the inner 
cavity of the CNTs and sealed with PPy via electropolymerization (Fig. 8). It was shown that 
the coatings not only significantly increased the amounts of electrically loaded and releasable 
drug, but also enabled a more linear and sustainable drug release profile, attributable to the 
incorporation of CNTs. Incorporation of CNTs into OCPs is also a viable approach to 
D 
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improving the electrode performance, especially for the application in high density chronic 
neural stimulation [72,73,74]. Pt microelectrodes coated with CNT-doped PPy or PEDOT 
exhibit remarkably lower impedance and higher safe charge injection limit, both by 1-2 
orders of magnitude in comparison to those coated with conventional OCPs. More 
importantly, these microelectrodes exhibit much improved mechanical and electrochemical 
stability during prolonged and intensive electrical stimulation, without any cracking or 
delamination of the coating materials. Formation of macroscopic cracks and/or delamination 
under stimulation has been reported in a number of studies for conventional OCP coatings 
[45,75,76], and is regarded as a critical barrier limiting the application of OCPs in neural 
interfacing. 
 
Fig. 8. Schematic of the drug loading and release process of CNT nanoreservoirs. (A) Drug 
solution is filled into the interior of acid treated CNTs through sonication. (B) Pyrrole is 
added to the suspension containing CNTs and the drug, and electropolymerization is carried 
out. (C) Drug is released from CNT nanoreservoirs to surroundings through diffusion or 
electrical stimulation. Reproduced with permission from [48]. 
 
3.2. OCP coatings for delivery of neuroactive molecules  
We have shown that neurotrophin-3 (NT3) and brain-derived neurotrophic factor (BDNF) 
can be incorporated into PPy [40,44] coatings and then released using a clinically relevant 
biphasic electrical stimulation (Fig. 9). The drug loading capacity and electrically controlled 
drug release efficacies are subject to parameters such as polymerisation time [40] and dopant 
structure etc [44]. These coatings have been shown to promote a significant increase in 
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neurite extension from spiral ganglion neuron explants in vitro [41], and some level of 
preservation of cochlea nerves in vivo [43]. Recently we reported on co-delivery of NT3 and 
BDNF to synergistically encourage neurite outgrowth from cochlea explants [77]. Last but 
not the least, concurrent electrical stimulation may work in concert with the released 
neurotrophins to promote neuron rescue [78,79]. All these capabilities are highly desirable 
for promoting the survival of auditory neurons and neurite outgrowth toward the electrode 
implant, especially the cochlear implant.  
 
Fig. 9. 125I NT3 release kinetics from stimulated and non-stimulated PPy/pTS/125I NT3-
coated electrodes. Cumulative release of 125I NT3 was 3.5-fold greater from stimulated 1.0 
cm2 PPy/pTS/125I NT3-coated electrodes compared to non-stimulated PPy/pTS/125I NT3-
coated electrodes over 7 days. Error bars indicate the standard error of the mean. Reproduced 
with permission from [43]. 
 
Our study [41], as well as others [27], has revealed that the environmental cue via cell 
adhesion molecules is essential for achieving optimal effect of neurotrophin on neurite 
extension. Indeed, controlling the presentation of cell adhesion molecules has been seen as an 
important strategy to improve neural-implant interfaces [80,81,82,83,84]. For instance, a 
synthetic protein bearing fibronectin fragments, SLPF, or a laminin fragment, CDPGYIGSR, 
was incorporated through the electrochemical deposition of PPy onto micro-machined silicon 
recording probes (Fig. 10A and B) [85]. Rat glial or neuroblastoma cells, were shown to 
preferentially attach to the neural probes coated with PPy/SLPF and PPy/CDPGYIGSR 
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composite, respectively (Fig. 10C). The PPy/SLPF coatings showed a lower charge capacity 
compared to control PPy/poly(styrene sulphonate) (PPy/PSS) coatings (Fig. 10D), but were 
still capable of recording good quality voltage signals from single neurons in the cerebellum 
of guinea pigs. In a different study [86], the same researchers entrapped an additional laminin 
fragment, RNIAEIIKDI, into PPy, which had a lower impedance and higher charge capacity 
compared to the CDPGYIGSR fragment mentioned above. Importantly, the PPy/peptide 
composites showed less astrocyte adhesion compared to bare gold electrodes, which is a 
promising characteristic for controlling the foreign body response surrounding an electrode.  
 
 
Fig. 10. (A) Optical micrograph of PPy/PSS coated 5-channel neural probe. (B) SEM images 
of PPy/SLPF SFP coated electrode sites (total charged passed, 4 µC). (C) Coated neural 
probe cultured with human neuroblastoma cells. (D) Cyclic voltammetry of PPy/SLPF coated 
electrode in comparison with bare gold and PPy/PSS. Adapted with permission from [85]. 
 
To address the growing need for both biocompatibility and bioactivity in advanced neural 
interfacing, coating structures for stimulation and recording electrodes are becoming 
increasingly sophisticated. Significant efforts are being put into hybrid coatings of OCP and 
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hydrogel to combine the advantages of the two types of materials, in particular low 
impedance, controlled release of bioactive molecules and biomechanical integrity with soft 
tissue [49,50,87,88]. This strategy is of particular interest in brain implants; the inclusion of 
an appropriately engineered hydrogel component in the coating is expected to minimise the 
mechanical mismatch between hard electrode and soft brain tissue, thereby reducing 
micromotion, and consequently micromotion associated inflammatory response and tissue 
damage.  
 
A number of methods have been developed for the preparation of hybrid OCP-hydrogel 
coatings [89]. A simple and popular approach is direct electrodeposition of OCPs in the 
hydrogel coating of an electrode [87,90]. With the hydrogel networks acting as a 3D 
template, cloud-like OCPs are produced vertically around the electrode site, with enormously 
larger effective surface area and consequently much lower in vitro impedance characteristics 
compared to those grown on flat electrode substrates (Fig. 11) [87]. Some level of 
improvement in device performance has recently been demonstrated in vivo. For example, 
deposition of PEDOT on the electrode sites has been shown to improve the acute neural 
recoding functionality of alginate hydrogel-coated neural probes implanted in the auditory 
cortex of guinea pigs [49]. Cochlear implants with multifunctional coatings comprised of 
PEDOT, arginine-glycine-aspartic acid (RGD)-functionalized alginate hydrogel and BDNF, 
were shown to improve the stability of in vivo impedance during 6 months implantation [50]. 
However, the presence of RGD and BDNF seemed to have no effect on the survival of spiral 
ganglion neuron. Further improvement in both material design and fabrication is required, in 
order to achieve the optimal effect of hybrid OCP-hydrogel coatings on the performance of 
implanted electrodes. 
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Fig. 11. Schematic of conventional OCP coating on the gold electrode (A) and cloud-like 
conducting polymer on the gold electrode polymerized through the hydrogel matrix (B).  
Optical microscope images of top view of the conducting polymer in the hydrogel coating 
(C). Adapted with permission from [87]. 
  
(C) 
(B) 
(A) 
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4. Conclusions 
Neuro-bionics provides new dimensions in both therapeutics and diagnostics. The biological 
processes at implanted electrode interfaces, in particular cellular reactions and subsequent 
tissue remodelling, determine the safety, function and longevity of neuro-bionic implants. 
The past few decades have seen significant progress in improving the electrode performance 
through optimising the properties of electromaterials including composition, surface 
roughness, porosity, nanofeatures and modulus. Whilst significant progress has been made in 
vitro, the improvement in in-vivo is limited, and often transient. Thus there is a high demand 
for bionic devices with in situ drug delivery capacity to assist in controlling the cellular and 
tissue processes at the electrode interface. 
 
The general considerations for a drug delivery system, such as biocompatibility, drug loading 
capacity, release efficiency and a desired dosage profile, are important. In addition, the 
introduction of the delivery system should not result in any adverse effects on the electrical 
properties of electrodes, they should be mechanically stable to endure the implantation 
process and prolonged use, and not cause additional inflammatory response. Furthermore, 
such systems should not significantly increase the footprint of the implanted device.  
 
Here we review a number of controlled delivery systems that have been developed in tandem 
with neuro-bionic devices. The majority of such systems are based on bioactive coatings that 
serve as reservoirs of bioactive molecules for local intervention to improve the 
biocompatibility (via minimising reactive cellular and tissue responses), and/or the 
neuroactivity (via promoting neural preservation and outgrowth) of the implanted electrodes. 
Both biocompatibility and neuroactivity are integral to the engineering of a chronically stable 
interface enabling efficient signal transmission from the device to the neuronal targets. 
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Integrating microfabricated channels into neural prostheses is discussed as an alternative 
approach, with the advantage of high temporal and volumetric resolution in delivering 
molecules. 
 
OCP based delivery systems have attracted increasing attention. This may be attributed to 
their unique capacity to simultaneously improve the electrical properties of the electrode, and 
to control the local biochemical environment at the electrode interface via electrically on-
demand delivery of bioactive molecules. 
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